Integrated or stand alone Drug Discovery services (from hit findings to IND), to discover and evaluate the therapies of tomorrow together.
A premium complete, integrated service offer for radiopharmaceuticals drug discovery and generation
Value creation through innovative technologies & R&D partnerships
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
For Oncodesign, artificial intelligence (AI) is a powerful tool for accelerating and making drug development more reliable.
Optimization of data use to enhance and accelerate Drug Discovery processes in oncology
For more than 25 years, Oncodesign has been investing in precision medicine innovation technologies, which are essential from the very first stages of the Drug Discovery process.
Oncodesign’s mission is to discover new innovative therapies that are effective against cancers and serious diseases with no known treatments.
| Broker | Analyst | Recommandation | TARGET PRICE |
 | Gilbert Ferrand | *buy | 20€ |
 | Fanny Meindre | **buy | 15€ |
 | Victor Floc’h | *na | 15€ |
 | Christophe Dombu | *strong buy | 16.4€ |
*Recommendations given November 3 and 4, 2020.
** Recommandations given June, 23, 2021.
18 rue Jean Mazen - FR - 21000 Dijon
Tel.+33 380 788 260
Receive our general letter or our financial news!
